Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
15 Dec 2023
15 Dec 2023
Historique:
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
Despite the introduction of several new agents for the treatment of bladder cancer (BC), intravesical BCG remains a first line agent for the management of non-muscle invasive bladder cancer. In this study we evaluated the antitumor efficacy in animal models of BC of a recombinant BCG known as BCG-
Identifiants
pubmed: 38168333
doi: 10.1101/2023.12.15.571740
pmc: PMC10760079
pii:
doi:
Types de publication
Preprint
Langues
eng